Cel-Sci Corporation (CVM)
Cel-Sci Corp has various promising products in the pipeline. Multikine has been shown to shrink and completely eliminate cancer tumors, and is finished with Phase II testing. See http://www.cel-sci.com for details of these and LEAPS.
Cancer – Multikine®
Multikine®, CEL-SCI’s flagship cancer product, is the first immunotherapeutic agent being developed as a first-line standard of care cancer treatment. Multikine® is a different kind of weapon in the fight against cancer; one that harnesses our body’s natural ability to fight tumors.
Multikine® is also the first of a new class of cancer immunotherapy drugs. It is the first comprehensive immunotherapy and the first Immune SIMULATOR.
Multikine® is the only immunotherapy that is able to directly affect both the tumor cells themselves and activate a robust anti-tumor immune response.
Infectious Diseases-L.E.A.P.S.™
L.E.A.P.S.™ is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S.™ compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.
This new technology has been shown in several animal models to preferentially direct immune response to a cellular (e.g. T-cell), humoral (antibody) or mixed pathway. Any disease for which antigenic epitope sequences have been identified, such as: infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer’s) are potential candidates for this technology platform.
Insider Purchases - 09/30/2009
http://www.sec.gov/Archives/edgar/data/725363/000123603109000024/xslF345X03/primary_doc.xml
http://www.sec.gov/Archives/edgar/data/725363/000123603109000023/xslF345X03/primary_doc.xml
http://www.sec.gov/Archives/edgar/data/725363/000123603109000022/xslF345X03/primary_doc.xml
Insider Transaction - 360,000 shares - 10/1/2009 - John Cirpriano
Who is John Cirpriano?
John Cipriano, has been CEL-SCI's Senior Vice President of Regulatory
Affairs since March 2004. Mr. Cipriano brings to CEL-SCI over 30 years of
experience in both biotech and pharmaceutical companies
. In addition, he held
positions at the United States Food and Drug Administration (FDA) as Deputy
Director, Division of Biologics Investigational New Drugs, Office of Biologics
Research and Review and was the Deputy Director, IND Branch, Division of
Biologics Evaluation, Office of Biologics. Mr. Cipriano completed his B.S. in
Pharmacy from the Massachusetts College of Pharmacy in Boston, Massachusetts and
his M.S. in Pharmaceutical Chemistry from Purdue University in West Lafayette,
Indiana.
http://www.secinfo.com/duWA1.u21.htm http://www.sec.gov/Archives/edgar/data/725363/000123603109000025/xslF345X02/primary_doc.xml
Rodman & Renshaw - $20,000,000 Purchase
Patents currently held: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=CEL-SCI&FIELD1=ASNM&co1=AND&TERM2=&FIELD2=&d=PTXT
Patents in pre-grant status: http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=CEL-SCI&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01
Centers for Disease Control and Prevention (CDC) added Cel Sci to the list of "vaccine and biologics manufacturers and distributors" - Cel-Sci Corp listed under CELS - http://www.cdc.gov/vaccinesafety/vaxtech/visi/standard_vaccine_manufacturer_abbreviations.doc